Listing 1 - 2 of 2 |
Sort by
|
Choose an application
Breast Cancer, Second Edition, is the seventh book in the M. D. Anderson Cancer Care Series. This book, like the others in this series, highlights M. D. Anderson Cancer Center’s multidisciplinary approach and reviews the entire spectrum of patient care, from prevention and screening through diagnosis and treatment through posttreatment follow-up and survivorship issues. This new edition of Breast Cancer has been extensively revised and updated. It covers newer approaches adopted since the first edition of this book was published in 2001, such as new options for breast cancer prevention, the role of MRI screening for women at high risk for breast cancer development, and integration of trastuzumab (Herceptin) into treatment regimens for early breast cancer. A number of new tables and figures have been added as well. In 19 comprehensive yet concise chapters, the experts at M. D. Anderson discuss primary prevention of breast cancer, screening for early detection of breast cancer, genetic predisposition to breast cancer and genetic counseling and testing, diagnostic imaging, pathology, surgical options, reconstructive surgery, radiation therapy, prognostic markers, standard and high-dose chemotherapy, hormonal therapy, gynecologic problems in breast cancer patients, posttreatment rehabilitation, menopausal health after breast cancer, and sexuality in breast cancer survivors. This thorough, practical volume, which includes more than 70 figures and 30 tables, is an essential clinical guide for oncologists, surgeons, internists, family practitioners, and other health care providers involved in the care of patients with breast cancer.
Breast --- Cancer. --- Oncology . --- Oncology. --- Tumors
Choose an application
The possibility of treating cancer, a disease defined by genetic defects, by introducing genes targeting these very alterations has led to an immense interest in gene therapy for cancer. Although incremental successes have been realized, enthusiasm for gene therapy has declined due to an increasing number of obstacles. These obstacles include vector systems that do not reach systemic metastases, therapeutic genes with redundant mec- nisms allowing for cellular resistance, and toxicities in clinical trials leading to premature closure of these studies. Different tactics to overcome or circumvent these obstacles have catalyzed the development of a wide range of gene therapy approaches. Thus far, almost two-thirds of gene therapy trials have focused on cancer. This reflects the concept that gene therapy approaches for the treatment of cancer do not necessarily require long-term expression of the gene as is necessary for the treatment of primary genetic defects like hemophilia or juvenile diabetes. Unlike the treatment of genetic defects, where expr- sion of the corrected gene needs to be strong, permanent and, sometimes regulated, tactics to treat tumors can be based on temporary and locally limited effects. In addition, cancer cells have different properties than normal cells and this allows for targeting gene therapy to specific cells, a major advantage over current antitumor therapies, which are also toxic to normal cells and tissues.
Cancer --- Gene therapy. --- Genetic aspects --- Treatment
Listing 1 - 2 of 2 |
Sort by
|